Sanara MedTech Inc.

NasdaqCM SMTI

Sanara MedTech Inc. Price to Earnings Ratio (P/E) on January 14, 2025: -33.94

Sanara MedTech Inc. Price to Earnings Ratio (P/E) is -33.94 on January 14, 2025, a 52.78% change year over year. Price to earnings ratio compares the stock price to earnings per share; higher P/E suggests expectations for future earnings growth.
  • Sanara MedTech Inc. 52-week high Price to Earnings Ratio (P/E) is -30.14 on October 01, 2024, which is 11.20% above the current Price to Earnings Ratio (P/E).
  • Sanara MedTech Inc. 52-week low Price to Earnings Ratio (P/E) is -76.06 on February 08, 2024, which is -124.13% below the current Price to Earnings Ratio (P/E).
  • Sanara MedTech Inc. average Price to Earnings Ratio (P/E) for the last 52 weeks is -49.11.
Key data
Date Price to Earnings Ratio (P/E) Price to Sales Ratio (P/S) Price to Book Ratio (P/B) Dividend Yield
Market news
Loading...
NasdaqCM: SMTI

Sanara MedTech Inc.

CEO Mr. Ronald T. Nixon
IPO Date April 7, 1994
Location United States
Headquarters 1200 Summit Avenue
Employees 107
Sector Health Care
Industries
Description

Sanara MedTech Inc. develops, markets, and distributes wound and skin care products to physicians, hospitals, clinics, and post-acute care settings in the United States. It offers CellerateRX Surgical Activated Collagen powder and gel that are used in a range of surgical specialties to help promote patient healing; Biako's Antimicrobial Skin and Wound Cleanser, a patented product that disrupts extracellular polymeric substances to eradicate mature biofilm microbes; Biako's Antimicrobial Wound Gel, an antimicrobial hydrogel wound dressing helps against planktonic microbes, as well as immature and mature biofilms; and Biako's Antimicrobial Skin and Wound Irrigation Solution. The company also provides HYCOL Hydrolyzed Collagen Powder and Gel, a medical hydrolysate of Type I bovine collagen for the management of full and partial thickness wounds, including pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers. In addition, it develops FORTIFY TRG, a freeze-dried, multi-layer small intestinal submucosa extracellular matrix sheet; FORTIFY FLOWABLE extracellular matrix, an advanced wound care device; and VIM Amnion Matrix, a single layer sheet of amnion tissue. The company was formerly known as WNDM Medical Inc. and changed its name to Sanara MedTech Inc. in May 2019. Sanara MedTech Inc. was incorporated in 2001 and is based in Fort Worth, Texas.

Similar companies

INFU

InfuSystem Holdings, Inc.

USD 7.87

-0.51%

HAE

Haemonetics Corporation

USD 79.96

0.69%

NVST

Envista Holdings Corp

USD 18.85

-0.74%

ATR

AptarGroup, Inc.

USD 154.61

0.47%

UTMD

Utah Medical Products, Inc.

USD 61.49

0.77%

PDEX

Pro-Dex, Inc.

USD 45.00

-3.72%

MMSI

Merit Medical Systems, Inc.

USD 99.89

4.44%

KRMD

KORU Medical Systems, Inc.

USD 4.07

3.04%

LMAT

LeMaitre Vascular, Inc.

USD 95.85

1.78%

ANGO

AngioDynamics, Inc.

USD 11.80

-5.30%

DXR

Daxor Corporation

USD 8.43

2.18%

POCI

Precision Optics Corporation, Inc.

USD 4.76

-2.46%

StockViz Staff

January 15, 2025

Any question? Send us an email